1. P1439: IMMUNE RESPONSE TO ANTI-SARS-COV-2 MRNA VACCINES IN MULTIPLE MYELOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. (23rd June 2022) Authors: Zaleska, J.; Kwaśnik, P.; Paziewska, M.; Purkot, J.; Szabelak, A.; Jurek, M.; Masny, N.; Dziatkiewicz, I.; Własiuk, P.; Skórka, K.; Stasiak, G.; Pronobis-Szczylik, B.; Piebiak, A.; Szymczyk, A.; Jarosz-Chudzik, K.; Bołkun, L.; Kozłowska, K.; Piszcz, J.; Subocz, E.; Hałka, J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1322 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1444: IMPACT OF CO-MORBIDITIES ON NON-RELAPSE MORTALITY AND CYTOKINE-RELEASE SYNDROME AFTER CD19 CAR-T CELL THERAPY - A RETROSPECTIVE STUDY FROM THE TCWP OF THE EBMT AND GOCART COALITION. (23rd June 2022) Authors: Basak, G.; Peczynski, C.; Koenecke, C.; Terwel, S.; Cabrerizo, Y.; Penack, O.; Moiseev, I.; Schoemans, H.; Fegueux, N.; Potter, V.; Zeerleder, S.; Yakoub-Agha, I.; Collin, M.; Schanz, U.; Dreger, P.; Blaise, D.; Besley, C.; Glass, B.; Mohty, M.; Chabannon, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1327 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1). (23rd June 2022) Authors: DeZern, A.; Marconi, G.; Deeren, D.; Diez Campelo, M.; Lübbert, M.; Krishnamurthy, P.; Nagy, Z.; Basak, G.; Jonášová, A.; Morozova, E.; Geissler, K.; Ofran, Y.; Kelley, H.; Volkert, A.; Baker, K.; Kang-Fortner, Q.; Hodgson, G.; Madigan, C.; Roth, D. A.; Kelly, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1800 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: SELECT-MDS-1 TRIAL IN PROGRESS: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF TAMIBAROTENE/AZACITIDINE VS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED (ND) ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS. (May 2023) Authors: Dezern, A.; Fenaux, P.; Deeren, D.; Campelo, M.; Lübbert, M.; Krishnamurthy, P.; Nagy, Z.; Basak, G.; Jonasova, A.; Geissler, K.; Ofran, Y.; Klimek, V.; Volkert, A.; Chisholm, J.; Hu, B.; Hodgson, G.; Roth, D.A.; Kelly, M.; Marconi, G. Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗